Lineage Cell Therapeutics, Inc. (LCTX) Shareholders’ equity 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) shareholders’ equity at each fiscal year-end, per SEC filings.
$44.5MFY2025 · since FY2016: $117.9M → $44.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $44.5M | -43.2% |
| FY2024 | $78.4M | +23.6% |
| FY2023 | $63.4M | -13.5% |
| FY2022 | $73.3M | -20.5% |
| FY2021 | $92.2M | -4.1% |
| FY2020 | $96.2M | -14.8% |
| FY2019 | $113.0M | +22.5% |
| FY2018 | $92.2M | -43.3% |
| FY2017 | $162.6M | +37.9% |
| FY2016 | $117.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice